SensoDetect – Patent Euroasia ready for national registration

Report this content

Sensodetect has been notified that EuroAsia patents 2108550EA has been granted.

SensoDetects patent attorney, Awapatent, has announced that the SensoDetects main portfolio is approved in the Euroasia (Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan) area. IP portfolio strenghtens through this in especially one very important market, Russia.

In these countries, there is similar problems in Psychiatry as in the rest of the world. Interest increase in mental health treatment where SensoDetect BERA can be used for "screening" or as a decision support. SensoDetect is now granted patents that further strengthens the protection in countries where there are multiple stakeholders concerning the SensoDetects platform BERA and associated analytical tools.

"We will immediately undertake a national registration in Rysssland as the market is very interesting for the future. Russia and several other countries in the former East is investing much in modern medical technology and it is important to be involved in such markets", says CEO Johan Olson

"I see that we continue strengthen our IP portfolio according to plan. Now in an area that represents a very big future market. Psychiatry in these countries are wrestling with the same challenges of mental health treatment as the rest of the world. I therefore see this as a very important milestone that allows us to move forward our positions and seek partners on the Russian market ", says Chairman Jan Andersson

Johan Olson

VD, SensoDetect Aktiebolag (publ)

Phone: +46 705 424600

e-mail: jo@sensodetect.com

 

Jan Andersson

Chairman of the board, SensoDetect Aktiebolag (publ)

Phone: +46 793 472280

E-mail: jan@sensodetect.com

This information is information that SensoDetect AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 5 2017.

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Tags:

Subscribe

Documents & Links

Quotes

We will immediately undertake a national registration in Rysssland as the market is very interesting for the future. Russia and several other countries in the former East is investing much in modern medical technology and it is important to be involved in such markets
CEO, Johan Olson, SensoDetect AB (publ.)
I see that we continue strengthen our IP portfolio according to plan. Now in an area that represents a very big future market. Psychiatry in these countries are wrestling with the same challenges of mental health treatment as the rest of the world. I therefore see this as a very important milestone that allows us to move forward our positions and seek partners on the Russian market
Chairman of the board, Jan Andersson, SensoDetect AB (publ.)